Tango Therapeutics (TNGX)

Executive Summary

Tango Therapeutics is a clinical-stage biotechnology company pioneering synthetic lethality-based cancer therapies. Its platform leverages CRISPR functional genomics to identify novel targets, with a pipeline focused on genetically defined patient populations. Lead programs include TNG908 (PRMT5 inhibitor for MTAP-deleted solid tumors) and TNG462 (next-generation PRMT5 inhibitor), both in Phase 1/2 trials. TNG260, a CoREST complex inhibitor, aims to restore anti-PD1 sensitivity in STK11-mutant NSCLC, while TNG348 (USP1 inhibitor) was terminated in 2024. The company also explores combinations, such as TNG462 with pembrolizumab. Tango's strategy addresses high unmet needs in hard-to-treat tumors, with initial data from multiple programs expected throughout 2026.

Upcoming Catalysts (preview)

• Q3 2026TNG260 + pembrolizumab Phase 1/2 data in STK11-mutant NSCLC40% success
• Q4 2026TNG462 + pembrolizumab Phase 1/2 preliminary efficacy data in solid tumors35% success
• Q3 2026TNG908 Phase 1/2 dose escalation and expansion update in MTAP-deleted tumors50% success